Webcast ImageWebcast
Clovis Oncology, Inc. Earnings Conference Call (Replay)
02/26/18 at 4:30 p.m. ET
Clovis Oncology, Inc. Earnings Conference Call
Monday, February 26, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Download Documentation Clovis Oncology, Inc. at the 36th Annual JP Morgan Conference Presentation
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.04 (0.07%)
Intraday High$59.24
Intraday Low$56.21
Data as of 03/23/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
03/23/18Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe
BOULDER, Colo.--(BUSINESS WIRE)--Mar. 23, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation fro... 
Printer Friendly Version 
03/23/18CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
Rubraca offers a new option for women with advanced BRCA mutant ovarian cancer with platinum-sensitive, relapsed or progressive disease, who are unable to tolerate further platinum based chemotherapy First PARP inhibitor recommended for treatment indication in the EU European Commission (EC) formal approval is anticipated Q2 2018 Once approved by the EC, Clovis plans to file a variation to the M... 
Printer Friendly Version 
03/08/18Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035
• Claims to be issued cover all commercial dosage strengths of Rubraca® • This will be the 10th Orange Book-listed patent for Rubraca BOULDER, Colo.--(BUSINESS WIRE)--Mar. 8, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims directed to high dosage strength ruc... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.